Navigation Links
Alexza Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
Date:11/21/2013

Latin America, Russia and the Commonwealth of Independent States countries.

For more information about Alexza, the Staccato system technology or the Company's development programs, please visit www.alexza.com.  For more information about ADASUVE, please visit www.adasuve.com

ADASUVE® and Staccato® are registered trademarks of Alexza Pharmaceuticals, Inc.

Safe Harbor Statement

The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs, including the ability of Alexza and our partners, Teva and Ferrer, to effectively and profitably commercialize ADASUVE, estimated product revenues and royalties associated with the sale of ADASUVE, the adequacy of the Company's capital to support the Company's operations, and the Company's ability to raise additional funds and the potential terms of such potential financings. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2012 and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announce
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012
2. Alexza Receives Complete Response Letter for Adasuve™ NDA
3. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alexza Pharmaceuticals Inc.
4. Alexza Announces Reverse Stock Split in Order to Maintain NASDAQ Listing
5. Alexza Secures a $20 Million Committed Equity Financing Facility with Azimuth Opportunity, L.P.
6. Alexza Announces Management Promotions
7. Alexza Reports 2012 Second Quarter Financial Results and Provides Business Update
8. Alexza Pharmaceuticals to Present at the Stifel Nicolaus 2012 Healthcare Conference
9. Alexza Pharmaceuticals Corporate Presentation to Be Webcast at Three Upcoming Investor Conferences
10. Alexza to Report 2012 Year-End Financial Results on Tuesday, March 26, 2013
11. Peter W. Schineller Joins Alexza Pharmaceuticals as Senior Vice President and Chief Commercial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... DUBLIN , June 02, 2015 ... the addition of the "2015 Strategies in ... to their offering. Highlights of the ... of the US tumor marker testing market. ... practice, as well as key economic, regulatory, demographic, ...
(Date:6/3/2015)... -- AVT, Inc. (OTC Markets: AVTC) ( www.autoretail.com ), ... that their customer, Pharmabox, has introduced the world,s 1 ... over 140 top selling brand name items typically found ... Aid-type store. As published in the ... -based Pharmabox worked with AVT to develop a ...
(Date:6/3/2015)... June 3, 2015  Halozyme Therapeutics, Inc. (NASDAQ: ... and license agreement with AbbVie (NYSE: ABBV ... compounds with Halozyme,s ENHANZE ™ platform. ... Halozyme will receive an initial $23 million payment, ... for each of up to nine collaboration targets. ...
Breaking Medicine Technology:United States Strategies in the Tumor Marker Testing Market 2015 2Pharmabox Introduces New Concept with a Boldly Designed Automated Retailing System 2Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie 2Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie 3
... Patient Safety Technologies, Inc. (OTC Bulletin Board: PSTX) (the "Company") announced ... financing.  The new capital will primarily be used to fund working ... , , ... has been appointed as President, Chief Executive Officer and Board ...
... PRINCETON, N.J. , June 25 Soligenix, ... a late-stage biopharmaceutical company, announced today the publication of ... of Vaccine , which describes protection from mucosal ... of RiVax™, the Company,s vaccine against ricin toxin. The ...
Cached Medicine Technology:Patient Safety Technologies Completes $6.0 Million Equity Financing 2Patient Safety Technologies Completes $6.0 Million Equity Financing 3Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration 2Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration 3Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration 4Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration 5Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration 6Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration 7
(Date:6/3/2015)... (PRWEB) June 03, 2015 On the heels ... $13 billion industry by 2020 ( click here to ... computer scientists believe Baltimore has the talent to ... in which genetic code and other biological data are collected ... disease. “Baltimore contains all the elements of a perfect ...
(Date:6/3/2015)... June 03, 2015 Alberto Grignolo, PhD, ... DIA’s upcoming Annual Meeting. DIA’s Global Inspire Award program ... of excellence, and commitment to service on a global ... Connector Award that annually recognizes one DIA member for ... the mission of DIA to foster innovation to improve ...
(Date:6/3/2015)... Z-Medica®, LLC, a leading developer and marketer ... designated as National Safety Month by the National Safety ... for its commitment to public safety. , The ... Aid Kits (IFAK) over 100 times in the past ... traffic accidents. Each kit is equipped with what’s needed ...
(Date:6/3/2015)... PA (PRWEB) June 03, 2015 Sitting ... can cause discomfort in the back, neck, shoulders and/or ... other musculoskeletal injuries. In addition, recent research links sitting ... number of chronic diseases. Fortunately, three inventors from Oakville, ... sit at a desk. , They have developed a ...
(Date:6/3/2015)... Implant design can have a profound influence ... bone to an implant surface. The unique triangular-shape of ... encourage bone regeneration, resulting in the gain of greater ... tissues for more esthetic restorations. , “It’s all in ... Implants. The triangular neck of the V3 provides solid ...
Breaking Medicine News(10 mins):Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 2Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 3Health News:Longtime DIA Champion and PAREXEL Executive Honored with Global Inspire Award at DIA’s Annual Meeting 2Health News:Longtime DIA Champion and PAREXEL Executive Honored with Global Inspire Award at DIA’s Annual Meeting 3Health News:Z-Medica Commends Tucson Police Department for Trauma Kit Utilization 2Health News:Adjustable Height Tabletop Unit Invented by Three InventHelp® Clients (TOR-9278) 2Health News:MIS Implants Launches Radically New V3 Dental Implant For Immediate Biological Benefits 2
... Area regional provider of hospice and palliative care, and its Foundation have merged ... Board of Directors. , ... Larkspur, CA (PRWEB) February 12, 2009 -- As of January ... hospice and palliative care, and its Foundation have become one entity, under the ...
... Mascara may not be the only thing that can be using ... has arrived. Latisse™ was developed through years of research by Allergan, ... eye care products. , ... Beverly Hills, CA (PRWEB) ...
... Inc., a,leading provider of kidney care services for ... failure, today announced the launch of the,DaVita(R) Glomerular ... and,iPod Touch. Available in over 50 countries in ... German, the DaVita GFR Calculator for,iPhone measures kidney ...
... Division: VETinfo SYSTEMS(TM)DULLES, Va., Feb. 12 RADinfo ... software solutions, proudly introduces a new division: VETinfo ... of RADinfo SYSTEMS , focused solely on ... developed dynamic digital software solutions to enhance patient ...
... An investor group in Trinity,Biotech plc (Nasdaq: ... of,diagnostic products, is delighted that Jim Merselis has joined ... support for Mr. Merselis, the,group has scheduled a conference ... am PT) on Tuesday, February 17, 2009. , ...
... could lead to new treatments for organ,s diseases that ... -- It may be possible to use skin cells ... researchers at the University of Wisconsin-Madison report. , In ... be turned back into stem cells. In this new ...
Cached Medicine News:Health News:Hospice By The Bay and Foundation Merge Under One Governing Board 2Health News:Hospice By The Bay and Foundation Merge Under One Governing Board 3Health News:Make Lashes Longer, Thicker, and Darker with Latisse™ 2Health News:Make Lashes Longer, Thicker, and Darker with Latisse™ 3Health News:DaVita Launches Kidney Calculator for iPhone and iPod Touch 2Health News:DaVita Launches Kidney Calculator for iPhone and iPod Touch 3Health News:RADinfo SYSTEMS(TM) is Pleased to Introduce Their Newly Established Division, VETinfo SYSTEMS(TM) 2
VIKIA Rota-Adeno is a rapid, qualitative, chromatographic immunoassay which simultaneously detects rotaviruses and adenoviruses in stool specimens. Rotaviruses and adenoviruses are responsible for,th...
A direct enzyme immunoassay for detection of gr. A rotavirus in fecal specimens....
The ELISA test is used for detection and semi quantitation of igG antibodies to proteinase 3(PR3) in human sera, as an aid to the diagnosis is of Wegener's granulomatosis....
ELISA for Anti-Proteinase 3 PR3 (cANCA)....
Medicine Products: